Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Capsugel, a business of Pfizer, has acquired FlexTab technology, developed over the past 8 years within GlaxoSmithKline (GSK).
Subscribe to our email newsletter
The FlexTab technology allows for a variety of fill materials, including powders, pellets, liquids, micro-tablets and tablets, and can even deliver separate liquid and powder active pharma ingredients (APIs) in one dose, Capsugel said.
The technology uses injection molding processes to produce unique capsule-shaped dosage forms that offer a new platform for formulating a wide range of new pharmaceutical and consumer health products.
Capsugel VP of R&D Keith Hutchison said they believe that the FlexTab technology’s unique performance characteristics and novel presentation will enable them to formulate the next generation of pharmaceutical and biotech products for customers.
"With fewer new drug entities coming to market, our customers are looking for other ways to improve the therapeutic effectiveness of existing API’s for patients and consumers, for example through better patient compliance and convenience," Hutchison said.